Abstract:Background Vasculogenic mimicry (VM) is a novel tumor blood supply in some highly aggressive malignant tumors. Recently, we reported VM existed in gallbladder carcinomas (GBCs) and the formation of the special passage through the activation of the PI3K/MMPs/Ln-5γ2 signaling pathway. GBC is a highly aggressive malignant tumor with disappointing treatments and a poor prognosis. Norcantharidin (NCTD) has shown to have multiple antitumor activities against GBCs, etc; however the exact mechanism is not thoroughly elucidated. In this study, we firstly investigated the anti-VM activity of NCTD as a VM inhibitor for GBCs and its underlying mechanisms. Methods In vitro and in vivo experiments to determine the effects of NCTD on proliferation, invasion, migration, VM formation, hemodynamic and tumor growth of GBC-SD cells and xenografts were respectively done by proliferation, invasion, migration assays, H&E staining and CD31-PAS double stainings, optic/electron microscopy, tumor assay, and dynamic micro-MRA. Further, immunohistochemistry, immunofluorescence, Western blotting and RT-PCR were respectively used to examine expression of VM signaling-related markers PI3-K, MMP-2, MT1-MMP and Ln-5γ2 in GBC-SD cells and xenografts in vitro and in vivo . Results After treatment with NCTD, proliferation, invasion, migration of GBC-SD cells were inhibited; GBC-SD cells and xenografts were unable to form VM-like structures; tumor center-VM region of the xenografts exhibited a decreased signal in intensity; then cell or xenograft growth was inhibited. Whereas all of untreated GBC-SD cells and xenografts formed VM-like structures with the same conditions; the xenograft center-VM region exhibited a gradually increased signal; and facilitated cell or xenograft growth. Furthermore, expression of MMP-2 and MT1-MMP products from sections/supernates of 3-D matrices and the xenografts, and expression of PI3-K, MMP-2, MM1-MMP and Ln-5γ2 proteins/mRNAs of the xenografts were all decreased in NCTD or TIMP-2 group; (all P < 0.01, vs . control group); NCTD down-regulated expression of these VM signaling-related markers in vitro and in vivo . Conclusions NCTD inhibited tumor growth and VM of human GBCs in vitro and in vivo by suppression of the PI3-K/MMPs/Ln-5γ2 signaling pathway. It is firstly concluded that NCTD may be a potential anti-VM agent for human GBCs.

Norcantharidin Blocks Wnt/β-catenin Signaling Via Promoter Demethylation of WIF-1 in Glioma.

Norcantharidin Inhibits Wnt Signal Pathway Via Promoter Demethylation of WIF-1 in Human Non-Small Cell Lung Cancer.

Berberine Inhibits Cell Growth Via Wnt/Beta-Catenin Signaling In Glioma

Cantharidin Inhibits Anti-Apoptotic Bcl-2 Family Proteins and Induces Apoptosis in Human Osteosarcoma Cell Lines MG-63 and MNNG/HOS Via Mitochondria-Dependent Pathway.

Norcantharidin inhibits tumor growth and vasculogenic mimicry of human gallbladder carcinomas by suppression of the PI3-K/MMPs/Ln-5γ2 signaling pathway

Norcantharidin Suppresses Colon Cancer Cell Epithelial-Mesenchymal Transition by Inhibiting the αvβ6-ERK-Ets1 Signaling Pathway

Norcantharidin Inhibits Cell Growth by Suppressing the Expression and Phosphorylation of Both EGFR and C-Met in Human Colon Cancer Cells

Norcantharidin Triggers Apoptotic Cell Death in Non-Small Cell Lung Cancer Via a Mitophagy-Mediated Autophagy Pathway

Anticancer activity and mechanisms of norcantharidin-Nd3II on hepatoma.

Norcantharidin inhibits the malignant progression of cervical cancer by inducing endoplasmic reticulum stress

Norcantharidin Inhibits Growth of Human Gallbladder Carcinoma Xenografted Tumors in Nude Mice by Inducing Apoptosis and Blocking the Cell Cycle in Vivo.

Norcantharidin Induces Melanoma Cell Apoptosis Through Activation of TR3 Dependent Pathway

Norcantharidin Triggers Cell Death and Dna Damage Through S-Phase Arrest and Ros-Modulated Apoptotic Pathways in Tsgh 8301 Human Urinary Bladder Carcinoma Cells

Cantharidin suppresses cell growth and migration, and activates autophagy in human non-small cell lung cancer cells

Norcantharidin Induces Autophagy-Related Prostate Cancer Cell Death Through Beclin-1 Upregulation by Mir-129-5p Suppression

A Potential Small-Molecule Synthetic Antilymphangiogenic Agent Norcantharidin Inhibits Tumor Growth and Lymphangiogenesis of Human Colonic Adenocarcinomas Through Blocking Vegf-A,-C,-D/Vegfr-2,-3 "Multi-Points Priming" Mechanisms in Vitro and in Vivo

Determination of Norcantharidin-Associated Proteins by Comparative Proteomic Analysis in Bgc-823 Cells

Norcantharidin Modulates Mir-655-regulated SENP6 Protein Translation to Suppresses Invasion of Glioblastoma Cells.

Inhibition Of Tumor Vasculogenic Mimicry And Prolongation Of Host Survival In Highly Aggressive Gallbladder Cancers By Norcantharidin Via Blocking The Ephrin Type A Receptor 2/Focal Adhesion Kinase/Paxillin Signaling Pathway

Norcantharidin Suppresses YD-15 Cell Invasion Through Inhibition of FAK/Paxillin and F-Actin Reorganization

Norcantharidin attenuates epidermal growth factor-induced proliferation, EMT and motility in ARPE-19 cells by modulating the AKT/snail/E-cadherin axis